Editorial: Gut-lung axis: tuberculosis and drug resistance

different organs and systems, impacting immunity, metabolism, and functions. Among these connections, the gut-lung axis stands out as a complex area with potential to transform treatment of tuberculosis (TB) and drug resistance. Moreover, the gut microbiota affects the metabolism of TB drugs. Mycobacterium tuberculosis infections are a global health issue requiring effective control measures, with the study of human microbiota playing a crucial role (Wu et al.).Understanding how the gut microbiota, immune system, and drug metabolism are interconnected can lead to targeted therapies addressing the root issues of TB infection and resistance.Imbalances in microbiota composition are significant factors in M. tuberculosis pathogenesis and drug metabolism. However, few studies have explored how M. tuberculosis infection interacts with gut-lung axis microbiota composition. This Research Topic aimed to uncover this connection, emphasizing the importance of the gut-lung axis and drug resistance in TB management strategies.The focus is on M. tuberculosis, but research on other Mycobacteriaceae strains is also included. Within this topic, 5 articles have been published, expanding our understanding of the role of the gut-lung axis in TB infection and drug resistance.Enjeti et al. examined the connections between TB infection and the gut-lung axis, highlighting the crucial role of gut microbiota in influencing lung immunity with signaling molecules like shortchain fatty acids (SCFAs). This interaction modulates inflammatory responses in disease conditions. The link between gut microbiota and lung immunity is suggested to be significantly